91 related articles for article (PubMed ID: 30792217)
1. Evaluation of Pharmacodynamic Responses to Cancer Therapeutic Agents Using DNA Damage Markers.
Wilsker DF; Barrett AM; Dull AB; Lawrence SM; Hollingshead MG; Chen A; Kummar S; Parchment RE; Doroshow JH; Kinders RJ
Clin Cancer Res; 2019 May; 25(10):3084-3095. PubMed ID: 30792217
[TBL] [Abstract][Full Text] [Related]
2. Can γH2AX be used to personalise cancer treatment?
Shah K; Cornelissen B; Kiltie AE; Vallis KA
Curr Mol Med; 2013 Dec; 13(10):1591-602. PubMed ID: 24206133
[TBL] [Abstract][Full Text] [Related]
3. Advances in DNA damage response inhibitors in colorectal cancer therapy.
Yu Y; Jia H; Zhang T; Zhang W
Acta Biochim Biophys Sin (Shanghai); 2024 Jan; 56(1):15-22. PubMed ID: 38115743
[TBL] [Abstract][Full Text] [Related]
4. BCL-3 loss sensitises colorectal cancer cells to DNA damage by targeting homologous recombination.
Parker C; Chambers AC; Flanagan DJ; Ho JWY; Collard TJ; Ngo G; Baird DM; Timms P; Morgan RG; Sansom OJ; Williams AC
DNA Repair (Amst); 2022 Jul; 115():103331. PubMed ID: 35468497
[TBL] [Abstract][Full Text] [Related]
5. Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic Cancers with DNA Damage Repair Deficiencies.
Restifo D; McDermott JR; Cvetkovic D; Dos Santos T; Ogier C; Surumbayeva A; Handorf EA; Schimke C; Ma C; Cai KQ; Olszanski AJ; Kathad U; Bhatia K; Sharma P; Kulkarni A; Astsaturov I
Mol Cancer Ther; 2023 Oct; 22(10):1182-1190. PubMed ID: 37552607
[TBL] [Abstract][Full Text] [Related]
6. Replicative stress in gastroesophageal adenocarcinoma is associated with chromosomal instability and sensitivity to DNA damage response inhibitors.
Sahgal P; Patil DT; Sztupinszki ZM; Tisza V; Spisak S; Huffman B; Prosz A; Singh H; Lazaro JB; Szallasi Z; Cleary JM; Sethi NS
bioRxiv; 2023 Mar; ():. PubMed ID: 37034740
[TBL] [Abstract][Full Text] [Related]
7. Replicative stress in gastroesophageal cancer is associated with chromosomal instability and sensitivity to DNA damage response inhibitors.
Sahgal P; Patil DT; Bala P; Sztupinszki ZM; Tisza V; Spisak S; Luong AG; Huffman B; Prosz A; Singh H; Lazaro JB; Szallasi Z; Cleary JM; Sethi NS
iScience; 2023 Nov; 26(11):108169. PubMed ID: 37965133
[TBL] [Abstract][Full Text] [Related]
8. Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer.
Dreyer SB; Upstill-Goddard R; Paulus-Hock V; Paris C; Lampraki EM; Dray E; Serrels B; Caligiuri G; Rebus S; Plenker D; Galluzzo Z; Brunton H; Cunningham R; Tesson M; Nourse C; Bailey UM; Jones M; Moran-Jones K; Wright DW; Duthie F; Oien K; Evers L; McKay CJ; McGregor GA; Gulati A; Brough R; Bajrami I; Pettitt S; Dziubinski ML; Candido J; Balkwill F; Barry ST; Grützmann R; Rahib L; ; ; Johns A; Pajic M; Froeling FEM; Beer P; Musgrove EA; Petersen GM; Ashworth A; Frame MC; Crawford HC; Simeone DM; Lord C; Mukhopadhyay D; Pilarsky C; Tuveson DA; Cooke SL; Jamieson NB; Morton JP; Sansom OJ; Bailey PJ; Biankin AV; Chang DK
Gastroenterology; 2021 Jan; 160(1):362-377.e13. PubMed ID: 33039466
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors.
Mittra A; Coyne GHOS; Zlott J; Kummar S; Meehan R; Rubinstein L; Juwara L; Wilsker D; Ji J; Miller B; Navas T; Ferry-Galow KV; Voth AR; Chang TC; Jiwani S; Parchment RE; Doroshow JH; Chen AP
Cancer Chemother Pharmacol; 2024 Mar; 93(3):177-189. PubMed ID: 38010394
[TBL] [Abstract][Full Text] [Related]
10. Myelosuppression Alleviation and Hematopoietic Regeneration by Tetrahedral-Framework Nucleic-Acid Nanostructures Functionalized with Osteogenic Growth Peptide.
Zhang T; Zhou M; Xiao D; Liu Z; Jiang Y; Feng M; Lin Y; Cai X
Adv Sci (Weinh); 2022 Sep; 9(27):e2202058. PubMed ID: 35882625
[TBL] [Abstract][Full Text] [Related]
11. Multiplexed-Based Assessment of DNA Damage Response to Chemotherapies Using Cell Imaging Cytometry.
Vezzio-Vié N; Kong-Hap MA; Combès E; Andrade AF; Del Rio M; Pasero P; Theillet C; Gongora C; Pourquier P
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628514
[TBL] [Abstract][Full Text] [Related]
12. ROADMAPS: An Online Database of Response Data, Dosing Regimens, and Toxicities of Approved Oncology Drugs as Single Agents to Guide Preclinical In Vivo Studies.
Hollingshead MG; Greenberg N; Gottholm-Ahalt M; Camalier R; Johnson BC; Collins JM; Doroshow JH
Cancer Res; 2022 Jun; 82(12):2219-2225. PubMed ID: 35472132
[TBL] [Abstract][Full Text] [Related]
13. Loss of ubiquitin-specific peptidase 18 destabilizes 14-3-3ζ protein and represses lung cancer metastasis.
Chen Z; Zheng L; Chen Y; Liu X; Kawakami M; Mustachio LM; Roszik J; Ferry-Galow KV; Parchment RE; Liu X; Andresson T; Duncan G; Kurie JM; Rodriguez-Canales J; Liu X; Dmitrovsky E
Cancer Biol Ther; 2022 Dec; 23(1):265-280. PubMed ID: 35387560
[TBL] [Abstract][Full Text] [Related]
14. PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components.
O'Sullivan Coyne G; Karlovich C; Wilsker D; Voth AR; Parchment RE; Chen AP; Doroshow JH
Onco Targets Ther; 2022; 15():165-180. PubMed ID: 35237050
[TBL] [Abstract][Full Text] [Related]
15. 5-Aza-4'-thio-2'-deoxycytidine, a New Orally Bioavailable Nontoxic "Best-in-Class": DNA Methyltransferase 1-Depleting Agent in Clinical Development.
Parker WB; Thottassery JV
J Pharmacol Exp Ther; 2021 Nov; 379(3):211-222. PubMed ID: 34503994
[TBL] [Abstract][Full Text] [Related]
16. Proteins from the DNA Damage Response: Regulation, Dysfunction, and Anticancer Strategies.
Molinaro C; Martoriati A; Cailliau K
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359720
[TBL] [Abstract][Full Text] [Related]
17. Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors.
Takebe N; Naqash AR; O'Sullivan Coyne G; Kummar S; Do K; Bruns A; Juwara L; Zlott J; Rubinstein L; Piekarz R; Sharon E; Streicher H; Mittra A; Miller SB; Ji J; Wilsker D; Kinders RJ; Parchment RE; Chen L; Chang TC; Das B; Mugundu G; Doroshow JH; Chen AP
Clin Cancer Res; 2021 Jul; 27(14):3834-3844. PubMed ID: 33863809
[TBL] [Abstract][Full Text] [Related]
18. The Interactions of DNA Repair, Telomere Homeostasis, and p53 Mutational Status in Solid Cancers: Risk, Prognosis, and Prediction.
Vodicka P; Andera L; Opattova A; Vodickova L
Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33513745
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomas.
Coyne GO; Kummar S; Meehan RS; Do K; Collins JM; Anderson L; Ishii K; Takebe N; Zlott J; Juwara L; Piekarz R; Streicher H; Sharon E; Rubinstein L; Voth AR; Lozier J; Dull AB; Wilsker D; Hinoue T; Laird PW; Ferry-Galow KV; Kinders RJ; Parchment RE; Doroshow JH; Chen AP
Oncotarget; 2020 Nov; 11(44):3959-3971. PubMed ID: 33216844
[TBL] [Abstract][Full Text] [Related]
20. Penetrating the brain tumor space with DNA damage response inhibitors.
Bindra RS
Neuro Oncol; 2020 Dec; 22(12):1718-1720. PubMed ID: 33059370
[No Abstract] [Full Text] [Related]
[Next] [New Search]
